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Background:  Interleukin-1b (IL-1b) is an inflammatory cytokine that suppresses cardiac contractility in cellular and animal models, referred to as 
circulating myocardial suppressant factor in sepsis. We hypothesize that increased plasma IL-1b activity in patients with acute decompensated heart 
failure (ADHF) may contribute to impaired cardiac function.
Methods:  Adult mice (N=5 per group) underwent baseline echocardiography to measure left ventricular ejection fraction (LVEF) and then 4 hours 
after receiving either plasma derived from healthy controls (0.2 mL), recombinant murine IL-1b (0.3 mcg/kg), or plasma from patients admitted with 
ADHF (0.2 mL), with or without pre-treatment with anakinra (recombinant human IL-1 receptor antagonist [10 mg/kg]).
Results:  Mice given recombinant IL-1b or plasma from patients with ADHF had significantly depressed LV systolic function at 4 hours after 
injection (LVFS reduction of 27% +/- 4% and 25 +/- 4%, respectively, P<0.05 versus baseline) when compared to mice receiving plasma from 
healthy controls. Pretreatment with anakinra prevented the systolic dysfunction (LVFS reduction of 2%, P<0.05 versus IL-1b or ADHF) seen in mice 
given the plasma from patients with ADHF, suggesting that the plasma of ADHF had sufficient IL-1 activity to induce systolic dysfunction.
Conclusions:  Patients with ADHF have enhanced plasma IL-1 activity which may contribute to impaired function. IL-1 blockade may represent a 
novel approach for the prevention or treatment of ADHF. 
